Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL995275 | 0.97 | TP53 (0.30) | ALDH1A1TP53TSHR | |
| Trifluoroacetic Acid SCHEMBL1890860 | 0.93 | TP53 (0.33) | TP53 | |
| Trifluoroacetic Acid SCHEMBL16288044 | 0.93 | — | — | |
| Trifluoroacetic Acid SCHEMBL522873 | 0.91 | — | — | |
| Trifluoroacetic Acid SCHEMBL16394297 | 0.91 | — | — | |
| Trifluoroacetic Acid SCHEMBL7065544 | 0.91 | — | — | |
| Trifluoroacetic Acid SCHEMBL21046091 | 0.89 | ATR (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL21046071 | 0.87 | DPP8 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL16289159 | 0.83 | — | — | |
| Dl-Dithiothreitol SCHEMBL28394515 | 0.83 | DPP4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874292-A | Multi-target chimeric peptide compound, preparation method and application thereof | 南通大学 | 2022-08-09 | — | — | CN | claimed |
| CN-116640100-A | Solid-phase synthesis method of fluororalrana | 河北圣雪大成制药有限责任公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023141536-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS | ABBVIE INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-116077720-A | Antibacterial double-layer hydrogel dressing and preparation method thereof | 西南交通大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-109153703-B | Immunomodulator | 百时美施贵宝公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-114874292-A | Multi-target chimeric peptide compound, preparation method and application thereof | 南通大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-107223129-B | Immunomodulator | 百时美施贵宝公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-107207568-B | Immunomodulator | 百时美施贵宝公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3423470-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-07-15 | — | — | US | disclosed |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-7425608-B2 | Method of making metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20060240481-A1 | Melanocortin Metallopeptode Combinatorial Libraries and Applications | PALATIN TECHNOLOGIES, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| US-7049398-B1 | Melanocortin metallopeptide constructs, combinatorial libraries and applications | PALATIN TECHNOLOGIES, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060003386-A1 | Combinatorial library of different sequence peptide members synthesized on solid phase, where each constituent library member includes peptide sequence of three or more amino acid residues bound to solid phase characterized by sequence of two or more amino acid residues forming a metal ion-binding domain | PALATIN TECHNOLOGIES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6660832-B1 | Cyclic peptide compounds with fused benzene rings; solid phase synthesis thereof; use as antibiotic to treat bacterial infection in mammals; may work by binding to RNA targets | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20020012948-A1 | Metallopeptide combinatorial libraries and applications | PALATIN TECHNOLOGIES, INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1027370-A2 | A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES THAT COVALENTLY MODIFY SUBSTRATE MOLECULES | PEPTIDE THERAPEUTICS LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999023109-A2 | A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES THAT COVALENTLY MODIFY SUBSTRATE MOLECULES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020012948-A1 | Metallopeptide combinatorial libraries and applications | SPPL2B, METAP2, PTMS | ALDH1A1 4694/4885TP53 1789/4885TSHR 1178/4885 |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | ALDH1A1 3138/4885TP53 100/4885TSHR 1405/4885 |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TLR7, TLR9, TLR8 | ALDH1A1 4407/4885TP53 2289/4885TSHR 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.